Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

被引：2

作者：

Martinez, Carmen ^{[1
]}

Rodriguez-Calvillo, Mercedes ^{[2
]}

Terol, Maria Jose ^{[3
]}

Xicoy, Blanca ^{[4
]}

Garcia-Sanz, Ramon ^{[5
]}

Perez-Ceballos, Elena ^{[6
]}

Cantalapiedra, Alberto ^{[7
]}

Domingo-Domenech, Eva ^{[8
]}

Hernandez, Miguel ^{[9
]}

Sampol, Antonia ^{[10
]}

Espeso, Manuel ^{[11
]}

Briones, Javier ^{[12
]}

Lopez, Javier ^{[13
]}

Sureda, Anna ^{[14
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Complejo Hosp Navarra, Navarra, Spain

[3] Hosp Clin Univ Valencia, Valencia, Spain

[4] Univ Autonoma Barcelona, IJC ICO Badalona, Hosp Germans Trias & Pujol, Badalona, Spain

[5] Univ Hosp Salamanca, Dept Haematol, Salamanca, Spain

[6] Hosp Morales Meseguer, Murcia, Spain

[7] Hosp Rio Hortega, Valladolid, Spain

[8] Inst Catala Oncol, Lhospitalet De Llobregat, Spain

[9] Hosp Univ Canarias, Tenerife, Spain

[10] Hosp Univ Son Dureta, Palma De Mallorca, Spain

[11] Hosp Reg Univ Carlos Haya, Malaga, Spain

[12] Autonomous Univ Barcelona, Barcelona, Spain

[13] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[14] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.1630.1630

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1630

引用

页数：2

共 47 条

[41] Efficacy of dose-dense R-CHOP-14 chemoimmunotherapy plus. pegfilgrastim for first-line treatment of diffuse large B-Cell lymphoma, (DLBCL) in low risk patients: An interim analysis of an open-label clinical trial in spain. on behalf of GEL/TAMO (Spanish group of lymphoma)
Gonzalez-Barca, Eva
Salar, Antonio
Bargay, Joan
Tomas, Jose F.
Canales, Miguel A.
Moraleda, Jose M.
Vidal, Maria Jesus
Ferrer, Secundino
Briones, Javier
Estany, Cristina
Gardella, Santiago
Llorente, Andres
Caballero, Dolores
BLOOD, 2007, 110 (11) : 1009A - 1009A
[42] PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup
Fornecker, Luc-Matthieu
Lazarovici, Julien
Aurer, Igor
Casasnovas, Rene-Olivier
Gac, Anne-Claire
Bonnet, Christophe
Bouabdallah, Krimo
Perrot, Aurore
Specht, Lena
Touati, Mohamed
Eisenmann, Jean Claude
Borel, Cecile
Stamatoullas, Aspasia
Nicolas-Virelizier, Emmanuelle
Pascal, Laurent
Lugtenburg, Pieternella
Bellei, Monica
Traverse-Glehen, Alexandra
Copie, Christiane
Hutchings, Martin
Versari, Annibale
Meignan, Michel
Federico, Massimo
Andre, Marc
BLOOD, 2017, 130
[43] Efficacy and safety of a single-course of Yttrium-90 Ibritumomab Tiuxetan for treatment of patients with relapsed or refractory mantle cell lymphoma after/not appropriate for autologous stem cell transplantation - Final analysis of a phase II trial of the European MCL network
Weigert, Oliver
von Schilling, Cluristoph
Rummel, Mathias J.
Pezzutto, Antonio
Unterhalt, Michael
Hiddemann, Wolfgang
Dreyling, Martin H.
BLOOD, 2007, 110 (11) : 197B - 197B
[44] Lisocabtagene Maraleucel (Liso-cel) vs Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 TRANSFORM Study
Glass, B.
Abramson, J. S.
Solomon, S. R.
Arnason, J. E.
Johnston, P. B.
Bachanova, V
Ibrahimi, S.
Mielke, S.
Mutsaers, P.
Hernandez-Ilizaliturri, F.
Izutsu, K.
Morschhauser, F.
Lunning, M. A.
Crotta, A.
Montheard, S.
Previtali, A.
Kamdar, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 272 - 273
[45] Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
Abramson, Jeremy S.
Solomon, Scott R.
Arnason, Jon E.
Johnston, Patrick B.
Glass, Bertram
Bachanova, Veronika
Ibrahimi, Sami
Mielke, Stephan
Mutsaers, Pim
Hernandez-Ilizaliturri, Francisco
Izutsu, Koji
Morschhauser, Franck
Lunning, Matthew A.
Crotta, Alessandro
Montheard, Sandrine
Previtali, Alessandro
Kamdar, Manali
BLOOD, 2022, 140 : 1581 - 1583
[46] Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -: early stopping after the first interim analysis.
Pfreundschuh, MG
Trümper, L
Ma, D
Österborg, A
Pettengell, R
Trneny, M
Shepherd, L
Waleswski, J
Zinzani, PL
Loeffler, M
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 558S - 558S
[47] Concordance between Bone Marrow and Peripheral Blood Samples for Assessment of FLT3 Internal Tandem Duplication (ITD) Mutations: Data from Patients Screened for Participation in Quantum-R, a Global, Randomized, Open-Label, Phase 3 Study Examining the Effect of Quizartinib Monotherapy Vs Salvage Chemotherapy on Overall Survival in Patients with FLT3 - ITD - Mutated AML Who Are Refractory to or Have Relapsed after First-Line Therapy
Khaled, Samer
Ganguly, Siddhartha
Perl, Alexander E.
Kobayashi, Ken
Berisha, Flora
Ding, Wei
Lameh, Jelveh
Martinelli, Giovanni
BLOOD, 2017, 130

← 1 2 3 4 5 →